62 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
to raise additional capital in sufficient amounts or on terms acceptable to it;
the efficacy and safety of the Company’s product candidate, obicetrapib … of future trial results and our clinical trials may fail to adequately demonstrate the safety and efficacy of obicetrapib.
The regulatory approval
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
to it;
the efficacy and safety of the Company’s product candidate, obicetrapib, as well as potential reimbursement and anticipated market size and market
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
to raise additional capital in sufficient amounts or on terms acceptable to it;
the efficacy and safety of the Company’s product candidate, obicetrapib … and safety of the Company’s product candidate, obicetrapib, as well as potential reimbursement and anticipated market size and market opportunity
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
acceptable to it;
the efficacy and safety of the Company’s product candidate, obicetrapib, as well as potential reimbursement and anticipated market size
POS AM
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
in sufficient amounts or on terms acceptable to it;
the efficacy and safety of the Company’s product candidate, obicetrapib, as well as potential
10-K
EX-10.8
n0xoaaowe1 v1
28 Feb 24
Annual report
8:00am
10-K
cwhyio
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
j4ij4v12p6tc9dfb73
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
4ufwfrlssp3vvxqzw4
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
5ogzyw2 1s1g32
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
cb4 lwd5xnx1
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
6tna wtk1uhrovfxm3
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
8-K
EX-99.1
dcurluxi4y0p993yb
4 Jan 24
NewAmsterdam Pharma Announces 2024 Strategic Priorities
8:08am
424B3
w3lprg6o
19 Dec 23
Prospectus supplement
4:36pm
F-3
EX-1.2
kfv pki0avx7hucbuua
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
ac3hntzktr08z0 vt0c
7 Dec 23
Shelf registration (foreign)
4:16pm
6-K
EX-99.1
xe7duw43fv4klt mo
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
6-K
EX-99.1
4a7p efk2
25 Sep 23
Current report (foreign)
8:10am
424B3
hcipqv0qqhz1lkugegs
21 Sep 23
Prospectus supplement
7:18am
6-K
suy6j8vc4worldx peae
21 Sep 23
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
7:14am